Hodgkin’s Lymphoma Market Size, Share, Industry, Forecast and outlook (2024-2031)

Hodgkin’s Lymphoma Market is segmented By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By Type (Nodular sclerosis Hodgkin lymphoma, Mixed cellularity Hodgkin lymphoma, Lymphocyte-rich Hodgkin lymphoma, Lymphocyte-depleted Hodgkin lymphoma), By Distribution channel (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Hodgkin’s Lymphoma Market Size

The Global Hodgkin’s Lymphoma Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.1 billion by 2031. The global Hodgkin’s lymphoma market is expected to exhibit a CAGR of 9.8% during the forecast period (2024-2031). The Hodgkin’s lymphoma market trends show rising research and development for diagnosis and treatment owing to the rising prevalence of lymphomas such as mixed cellularity Hodgkin’s lymphoma or MCCHL or nodular sclerosis Hodgkin’s lymphoma or NSCHL and increasing clinical trials. 

Furthermore, the rising government initiatives and support, together with rising demand for treatment at the point of care, is driving up the Hodgkin’s lymphoma market size. The market is experiencing a growth in demand from North American areas as a result of the development of research in these fields. Significant competitors like Actinium Pharmaceuticals, Inc., Seagen Inc., F. Hoffmann-La Roche Ltd and ,others actively operating in the market.

Market Summary

To know more insights - Download Sample

Market Dynamics

Rising Technological Advancements Drive the Growth of the Hodgkin’s Lymphoma Market

Over the past few years, the arsenal of HD treatments has quickly advanced beyond conventional cytotoxic chemotherapy regimens. Although ABVD (Doxorubicin, Vinblastine, Bleomycin and Dacarbazine) and BEACOPPesc (Escalated Dose of Bleomycin, Etoposide, Cyclophosphamide, Vincristine, Procarbazine and Prednisone) continue to be the gold standard of care in the management of Hodgkin's Disease, both have limitations in terms of short- and long-term toxicities. 

It is promising to see drugs like checkpoint inhibitors and brentuximab treatment advancing in the relapsed/refractory context. It is also reassuring to see a variety of ongoing trials examining the function of these drugs alone, in various combinations and conjunction with other HD therapy approaches.

Rising Research and Development and Novel Product Launches creates lucrative Opportunities  for Manufacturers

There is a growing Hodgkin’s lymphoma market opportunity owing to rising advancements and research and development owing to the increasing prevalence of Hodgkin’s lymphoma. The rising studies by major key players are also a Hodgkin’s lymphoma market trend driving the market. 

Researchers supported by the NCI are advancing our knowledge of lymphoma treatment. The lymphatic system, a component of the body's immune system, is where every lymphoma begins. The disease has more than 70 distinct subgroups. 

Scientists are now able to create more specialized treatments for different subtypes of lymphoma thanks to advances in our knowledge of the gene alterations that can cause the disease. 

To lessen the long-term negative effects and enhance survivors' quality of life, researchers are now concentrating on modifying conventional therapy regimens. The small percentage of people whose cancer does recur are also being treated with improved methods. 

Complications Associated With the Treatments Will Hamper the Growth of the Market. 

However, numerous complications are associated with the treatment of Hodgkin’s lymphoma. Tiredness, hair loss, skin rashes, and infertility, are a few adverse effects that may be permanent or temporary.

Hodgkin lymphoma survivors are more susceptible to developing lymphoma, leukemia, and other cancers in subsequent years. This risk is substantially increased by chemotherapy and radiation therapy. After receiving treatment for Hodgkin lymphoma, second cancers, like breast cancer and lung cancer, typically take longer than 10 years to manifest.   

Market Segment Analysis

The global Hodgkin’s lymphoma market is segmented based on therapy, type, end-user and region.

Owing to Advantages, the Chemotherapy Segment Accounted for Approximately 47.7% of the Hodgkin’s Lymphoma Market Share

Chemotherapy is a form of cancer care in which drugs are used to eradicate cancer cells. Depending on the current state of the malignancy, it can be delivered in a variety of methods. Patients typically undergo intravenous chemotherapy (a drip of chemotherapy administered straight into a vein) if medical professionals believe that the malignancy is treatable. 

The patient might simply need to consume chemotherapy pills to help with symptom relief if a cure is doubtful. Chemotherapy is often administered on an outpatient basis over the course of a few months, so the patient shouldn't need to spend the night in the hospital. A lengthier hospital stay can be required, nevertheless, if the symptoms or treatment side effects are extremely bothersome at some points.

The most important adverse effect of chemotherapy is the possibility of bone marrow destruction. This can obstruct the generation of normal blood cells and lead to issues including exhaustion, increased susceptibility to infection, shortness of breath, bleeding and bruising more frequently.

Market Geographical Share

North America Accounted for Approximately 40.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for Hodgkin’s lymphoma for treatment purposes in healthcare, manufacturers in North America have the chance of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for Hodgkin’s lymphoma. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for treatment and increase in biopharmaceutical establishment across the region are also contributing to the growth of Hodgkin’s lymphoma market share of this region. 

The primary healthcare organizations and businesses' joint research endeavors as well as new product development that continuously aims to enhance available treatment options are also expected to contribute to the rising demand. 

Individuals are becoming more aware of various advanced techniques that are being studied for the treatment leading to the expansion of the market in this region. The above-mentioned factors further prove North America's dominance on a global scale.

Market Key Players

The major global players in the Hodgkin’s lymphoma market include Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Seagen Inc., Ono Pharmaceutical Co., Ltd., AstraZeneca, Inc., Actinium Pharmaceuticals, Inc., Pfizer Inc., Affimed GmbH and Incyte among others. 

COVID-19 Impact on Market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global Hodgkin’s lymphoma market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global Hodgkin’s lymphoma market growth over the forecast period.

By Therapy

• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Others

By Type

• Nodular Sclerosis Hodgkin Lymphoma or NSCHL
• Mixed Cellularity Hodgkin Lymphoma or MCCHL
• Lymphocyte-rich Hodgkin Lymphoma
• Lymphocyte-depleted Hodgkin Lymphoma
• Others

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 11, 2023, a phase 1 clinical study of the world's first bispecific antibody anti-CD47/PD-L1, IBI322 for the treatment of patients with classic Hodgkin lymphoma who are anti-PD-(L)1-resistant, was unveiled at the 28th Annual Meeting of the American Society of Clinical Oncology (ASCO) in an oral presentation. This information was released by Innovent Biologics, Inc., a premier biopharmaceutical company.
• On May 23, 2023, The U.S. Food and Drug Administration (FDA) approved Affimed N.V.'s IND application for the simultaneous use of AFM13, its first-in-class bispecific tetravalent innate cell engager (ICE) and AB-101, Artiva Biotherapeutics Inc., an oncology company's clinical-stage, non-genetically modified, off-the-shelf, cryopreserved, allogeneic cord blood-delivered immunotherapy.
• On May 1, 2023, Biopharmaceutical company Bristol Myers Squibb recently released positive topline outcomes from two studies, TRANSCEND FL and TRANSCEND NHL 001, both of which evaluated Breyanzi (lisocabtagene maraleucel) for individuals with refractory or relapsed B-cell non-Hodgkin lymphoma. TRANSCEND FL was an open-label, global, multicenter, Phase 2 single-arm study evaluating Breyanzi in patients Results demonstrated that both studies accomplished the main objective of the overall response level, with Breyanzi showing statistically important and clinically significant responses in FL and MCL that had relapsed or had become resistant to treatment.  

Why Purchase the Report?

• To visualize the global Hodgkin’s lymphoma market segmentation based on therapy, type, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Hodgkin’s lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Hodgkin’s lymphoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2024

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies